FGFR2 and cholangiocarcinoma: Recently, Fibroblast growth factor receptor (FGFR) inhibitor pemigatinib was approved for treatment of CCA patients with Fibroblast growth factor receptor 2 (FGFR2) fusions or mutations, after demonstrating an objective response rate of 35.5% and a durable response of ≥ 12 months in 37% of the responders in a phase 2 clinical trial (Abou-Alfa et al. 2020).